BRISTOL MYERS SQUIBB
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1989-01-01
- Employees
- 30K
- Market Cap
- $97.5B
- Website
- https://www.bms.com/
A Dose Escalation and Combination Immunotherapy Study to Evaluate BMS-986226 Alone or in Combination With Nivolumab or Ipilimumab in Patients With Advanced Solid Tumors
Phase 1
Terminated
- Conditions
- CancerTumorsNeoplasmMalignancy
- Interventions
- First Posted Date
- 2017-08-16
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 80
- Registration Number
- NCT03251924
- Locations
- 🇺🇸
Local Institution - 0001, Philadelphia, Pennsylvania, United States
🇺🇸Local Institution - 0012, Saint Louis, Missouri, United States
🇺🇸Local Institution - 0002, Hackensack, New Jersey, United States
Pharmacokinetics and Metabolism Study in Healthy Male Participants
- First Posted Date
- 2017-08-11
- Last Posted Date
- 2017-11-06
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 9
- Registration Number
- NCT03247283
- Locations
- 🇺🇸
Covance Clinical Research Unit, Inc., Madison, Wisconsin, United States
A Study of BMS-986195 in Healthy Male Subjects
- First Posted Date
- 2017-08-10
- Last Posted Date
- 2018-01-05
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 24
- Registration Number
- NCT03245515
- Locations
- 🇳🇱
Local Institution, Groningen, Netherlands
A Study of Safety, Tolerability, and the Effects Two ND-L02-s0201 Have on the Body
- First Posted Date
- 2017-08-07
- Last Posted Date
- 2017-08-07
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 12
- Registration Number
- NCT03241264
To Evaluate the Safety and Pharmacokinetics of BMS-986177 in Healthy Japanese Participants
- First Posted Date
- 2017-07-21
- Last Posted Date
- 2018-06-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 33
- Registration Number
- NCT03224260
- Locations
- 🇺🇸
West Coast Clinical Trials, Anaheim, California, United States
A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC
Phase 3
Completed
- Conditions
- Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2017-07-12
- Last Posted Date
- 2024-12-24
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 719
- Registration Number
- NCT03215706
- Locations
- 🇺🇸
Local Institution - 0091, Wichita, Kansas, United States
🇺🇸Local Institution - 0004, Lexington, Kentucky, United States
🇦🇺Local Institution - 0086, Gosford, New South Wales, Australia
Pharmacokinetics and Metabolism of [14C] BMS-986231 in Healthy Male Participants
- First Posted Date
- 2017-07-07
- Last Posted Date
- 2017-08-01
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 5
- Registration Number
- NCT03210909
- Locations
- 🇺🇸
Covance Clinical Research Unit, Madison, Wisconsin, United States
Early Post-marketing Study of Daclatasvir (Daklinza®) + Asunaprevir (Sunvepra®) in the Treatment of Chronic Hepatitis C (CHC) in Adults
Withdrawn
- Conditions
- Hepatitis C
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2017-07-05
- Last Posted Date
- 2022-05-27
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03208322
- Locations
- 🇲🇽
Local Institution, Magdalena De Las Salinas, Distrito Federal, Mexico
The Effectiveness of Nivolumab Monotherapy as First-Line Therapy in Adults With Advanced Melanoma in Germany
Withdrawn
- Conditions
- Melanoma
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2018-04-09
- Lead Sponsor
- Bristol-Myers Squibb
- Registration Number
- NCT03205722
A Retrospective, Observational Study on the Effectiveness of Daclatasvir-Containing Regimens in Patients in KSA, UAE and Qatar
Completed
- Conditions
- Hepatitis C
- Interventions
- Other: Non-Interventional
- First Posted Date
- 2017-07-02
- Last Posted Date
- 2017-10-11
- Lead Sponsor
- Bristol-Myers Squibb
- Target Recruit Count
- 182
- Registration Number
- NCT03205618
- Locations
- 🇸🇦
Local Institution, Riyadh-11211, Saudi Arabia
© Copyright 2025. All Rights Reserved by MedPath